TAMPA, Fla.--(BUSINESS WIRE)--In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases.
Help employers find you! Check out all the jobs and post your resume.